本論文の作成ならびに本研究の遂行にあたり、終始御指導、御鞭撻を賜りました神戸学院 大学薬学部臨床薬学研究室 徳山 尚吾 教授に心より感謝申し上げます。
本論文の作成にあたり、御校閲ならびに御助言を賜りました神戸学院大学薬学部 岡本 正志 教授、糟谷 史代 教授に心から感謝致します。
HMGB1 の実験に際し、抗 HMGB1 抗体を御供与頂きました岡山大学大学院医歯薬学総
合研究科薬理学分野 西堀 正洋 教授、劉 克約 非常勤研究員に深く感謝を申し上げます。
本研究の遂行ならびに論文作成に際し、多大なる御指導、御助言を賜りました、神戸学院 大学薬学部臨床薬学研究室 中本 賀寿夫 講師に心から御礼申し上げます。
また、温かい励ましと御協力を頂きました本研究室の皆様および卒業生の皆様に心から 感謝致します。
末筆になりましたが、これまで大変な心配とご苦労をおかけしたにも関わらず、温かく見 守り、多大なるご支援を頂きました家族に心より感謝の意を表します。
48
引用文献
1. Hackett M. L., et al. Frequency of depression after stroke: a systematic review of observational studies. Stroke 36, 1330–40 (2005).
2. Kumar B., et al. Central poststroke pain: a review of pathophysiology and treatment. Anesth.
Analg. 108, 1645–57 (2009).
3. Yamaguchi T., et al. Alteplase at 0.6 mg/kg for acute ischemic stroke within 3 hours of onset:
Japan Alteplase Clinical Trial (J-ACT). Stroke 37, 1810–5 (2006).
4. Watanabe T., et al. [Research and development of the free radical scavenger edaravone as a neuroprotectant]. Yakugaku Zasshi 124, 99–111 (2004).
5. Woolf C. J. What is this thing called pain? J. Clin. Invest. 120, 3742–4 (2010).
6. Spiegel D., et al. Pain and depression in patients with cancer. Cancer 74, 2570–2578 (1994).
7. Gierthmühlen J., et al. Neuropathic Pain. Semin. Neurol. 36, 462–468 (2016).
8. Khedr E. M., et al. Longlasting antalgic effects of daily sessions of repetitive transcranial
magnetic stimulation in central and peripheral neuropathic pain. J. Neurol. Neurosurg. Psychiatry 76, 833–8 (2005).
9. Lampl C., et al. Amitriptyline in the Prophylaxis of Central Poststroke Pain. Stroke 33, 3030–
3032 (2002).
10. Kim J. S. Post-stroke pain. Expert Rev. Neurother. 9, 711–21 (2009).
11. Garbuzova-Davis S., et al. Blood-Spinal Cord Barrier Alterations in Subacute and Chronic Stages of a Rat Model of Focal Cerebral Ischemia. J. Neuropathol. Exp. Neurol. 75, 673–88 (2016).
12. Kuboyama K., et al. Reduced spinal microglial activation and neuropathic pain after nerve injury in mice lacking all three nitric oxide synthases. Mol. Pain 7, 50 (2011).
13. Cooke J. P., et al. DDAH says NO to ADMA. Arterioscler. Thromb. Vasc. Biol. 31, 1462–4 (2011).
14. Das N., et al. HMGB1 Activates Proinflammatory Signaling via TLR5 Leading to Allodynia. Cell Rep. 17, 1128–1140 (2016).
15. Nakamura Y., et al. Neuropathic pain in rats with a partial sciatic nerve ligation is alleviated by intravenous injection of monoclonal antibody to high mobility group box-1. PLoS One 8, e73640 (2013).
16. DʼMello R., et al. Dimethylarginine dimethylaminohydrolase 1 is involved in spinal nociceptive plasticity. Pain 156, 2052–60 (2015).
17. Suyama H., et al. Analgesic effect of intrathecal administration of orexin on neuropathic pain in rats. In Vivo 18, 119–23
18. Azhdari-Zarmehri H., et al. Orexin-A microinjection into the rostral ventromedial medulla causes antinociception on formalin test. Pharmacol. Biochem. Behav. 122, 286–90 (2014).
49
19. Mohammad-Pour Kargar H., et al. Microinjection of orexin-A into the rat locus coeruleus nucleus induces analgesia via cannabinoid type-1 receptors. Brain Res. 1624, 424–432 (2015).
20. Zhu Y., et al. Orexin receptor type-1 couples exclusively to pertussis toxin-insensitive G-proteins, while orexin receptor type-2 couples to both pertussis toxin-sensitive and -insensitive G-proteins.
J. Pharmacol. Sci. 92, 259–66 (2003).
21. Dohi K., et al. CSF orexin A concentrations and expressions of the orexin-1 receptor in rat hippocampus after cardiac arrest. Neuropeptides 40, 245–50 (2006).
22. Inutsuka A., et al. The integrative role of orexin/hypocretin neurons in nociceptive perception and analgesic regulation. Sci. Rep. 6, 29480 (2016).
23. Chen T., et al. Top-down descending facilitation of spinal sensory excitatory transmission from the anterior cingulate cortex. Nat. Commun. 9, 1886 (2018).
24. Garbuzova-Davis S., et al. Blood-Spinal Cord Barrier Alterations in Subacute and Chronic Stages of a Rat Model of Focal Cerebral Ischemia. J. Neuropathol. Exp. Neurol. 75, 673–88 (2016).
25. Dang G., et al. Alterations in the spinal cord and ventral root after cerebral infarction in non-human primates. Restor. Neurol. Neurosci. 36, 729–740 (2018).
26. Freire M. A. M., et al. Pain modulation by nitric oxide in the spinal cord. Front. Neurosci. 3, 175–81 (2009).
27. Koyanagi S., et al. Glucocorticoid regulation of ATP release from spinal astrocytes underlies diurnal exacerbation of neuropathic mechanical allodynia. Nat. Commun. 7, 13102 (2016).
28. Ji R.-R., et al. Emerging targets in neuroinflammation-driven chronic pain. Nat. Rev. Drug Discov. 13, 533–48 (2014).
29. Shih H.-C., et al. Targeting brain-derived neurotrophic factor in the medial thalamus for the treatment of central poststroke pain in a rodent model. Pain 158, 1302–1313 (2017).
30. Choi S.-R., et al. Spinal Nitric Oxide Synthase Type II Increases Neurosteroid-metabolizing Cytochrome P450c17 Expression in a Rodent Model of Neuropathic Pain. Exp. Neurobiol. 28, 516–528 (2019).
31. Iadecola C., et al. Inducible nitric oxide synthase gene expression in brain following cerebral ischemia. J. Cereb. Blood Flow Metab. 15, 378–84 (1995).
32. Hervera A., et al. The spinal cord expression of neuronal and inducible nitric oxide synthases and their contribution in the maintenance of neuropathic pain in mice. PLoS One 5, e14321 (2010).
33. Yang Y., et al. Role of nitric oxide synthase in the development of bone cancer pain and effect of L-NMMA. Mol. Med. Rep. 13, 1220–6 (2016).
34. Hu X., et al. Vascular Endothelial-Specific Dimethylarginine Dimethylaminohydrolase-1–
Deficient Mice Reveal That Vascular Endothelium Plays an Important Role in Removing Asymmetric Dimethylarginine. Circulation 120, 2222–2229 (2009).
35. Leiper J. M., et al. Identification of two human dimethylarginine dimethylaminohydrolases with
50
distinct tissue distributions and homology with microbial arginine deiminases. Biochem. J. 343 Pt 1, 209–14 (1999).
36. Tamiya S., et al. Establishment of a central post-stroke pain model using global cerebral ischaemic mice. J. Pharm. Pharmacol. 65, 615–20 (2013).
37. Hylden J. L., et al. Intrathecal morphine in mice: a new technique. Eur. J. Pharmacol. 67, 313–6 (1980).
38. Nakamoto K., et al. The activation of supraspinal GPR40/FFA1 receptor signalling regulates the descending pain control system. Br. J. Pharmacol. 172, 1250–62 (2015).
39. Nawa A., et al. Inducible nitric oxide synthase-mediated decrease of intestinal P-glycoprotein expression under streptozotocin-induced diabetic conditions. Life Sci. 86, 402–9 (2010).
40. Harada S., et al. Involvement of GPR40, a long-chain free fatty acid receptor, in the production of central post-stroke pain after global cerebral ischemia. Eur. J. Pharmacol. 744, 115–123 (2014).
41. Mihara Y., et al. Involvement of spinal NR2B-containing NMDA receptors in oxaliplatin-induced mechanical allodynia in rats. Mol. Pain 7, 8 (2011).
42. Zhang P., et al. Repetitive ischemia increases myocardial dimethylarginine dimethylaminohydrolase 1 expression. Vasc. Med. 22, 179–188 (2017).
43. Qi J., et al. Rab7b Overexpression-Ameliorated Ischemic Brain Damage Following tMCAO Involves Suppression of TLR4 and NF-κB p65. J. Mol. Neurosci. 68, 163–170 (2019).
44. Dang G., et al. Dynamic secondary degeneration in the spinal cord and ventral root after a focal cerebral infarction among hypertensive rats. Sci. Rep. 6, 22655 (2016).
45. Ghebremariam Y. T., et al. A novel and potent inhibitor of dimethylarginine
dimethylaminohydrolase: a modulator of cardiovascular nitric oxide. J. Pharmacol. Exp. Ther.
348, 69–76 (2014).
46. Leiper J. M. The DDAH-ADMA-NOS pathway. Ther. Drug Monit. 27, 744–6 (2005).
47. Wang H., et al. DDAH1 plays dual roles in PM2.5 induced cell death in A549 cells. Biochim.
Biophys. Acta 1860, 2793–801 (2016).
48. Wang S., et al. Dimethylarginine dimethylaminohydrolase 1 regulates nerve growth factor-promoted differentiation of PC12 cells in a nitric oxide-dependent but asymmetric
dimethylargenine-independent manner. J. Neurosci. Res. 90, 1209–17 (2012).
49. Luo Y., et al. Asymmetric dimethylarginine exacerbates Aβ-induced toxicity and oxidative stress in human cell and Caenorhabditis elegans models of Alzheimer disease. Free Radic. Biol. Med.
79, 117–26 (2015).
50. Goodwin G. H., et al. A new group of chromatin-associated proteins with a high content of acidic and basic amino acids. Eur. J. Biochem. 38, 14–9 (1973).
51. Wang H., et al. HMG-1 as a late mediator of endotoxin lethality in mice. Science 285, 248–51 (1999).
51
52. Zhang J., et al. Anti-high mobility group box-1 monoclonal antibody protects the blood-brain barrier from ischemia-induced disruption in rats. Stroke 42, 1420–8 (2011).
53. Yamasoba D., et al. Peripheral HMGB1-induced hyperalgesia in mice: Redox state-dependent distinct roles of RAGE and TLR4. J. Pharmacol. Sci. 130, 139–42 (2016).
54. Muhammad S., et al. The HMGB1 receptor RAGE mediates ischemic brain damage. J. Neurosci.
28, 12023–12031 (2008).
55. Qiu J., et al. High-mobility group box 1 promotes metalloproteinase-9 upregulation through Toll-like receptor 4 after cerebral ischemia. Stroke 41, 2077–82 (2010).
56. Ren P.-C., et al. High-mobility group box 1 contributes to mechanical allodynia and spinal astrocytic activation in a mouse model of type 2 diabetes. Brain Res. Bull. 88, 332–7 (2012).
57. Tong W., et al. Spinal high-mobility group box 1 contributes to mechanical allodynia in a rat model of bone cancer pain. Biochem. Biophys. Res. Commun. 395, 572–6 (2010).
58. Zou J. Y., et al. Release of neuronal HMGB1 by ethanol through decreased HDAC activity activates brain neuroimmune signaling. PLoS One 9, e87915 (2014).
59. Harris H. E., et al. HMGB1: a multifunctional alarmin driving autoimmune and inflammatory disease. Nat. Rev. Rheumatol. 8, 195–202 (2012).
60. Levenson J. M., et al. Regulation of histone acetylation during memory formation in the hippocampus. J. Biol. Chem. 279, 40545–59 (2004).
61. Simon R. P., et al. Blockade of N-methyl-D-aspartate receptors may protect against ischemic damage in the brain. Science 226, 850–2 (1984).
62. Danaher R. J., et al. Histone deacetylase inhibitors prevent persistent hypersensitivity in an orofacial neuropathic pain model. Mol. Pain 14, 1744806918796763 (2018).
63. Zhang H., et al. Dorsal Root Ganglion Infiltration by Macrophages Contributes to Paclitaxel Chemotherapy-Induced Peripheral Neuropathy. J. Pain 17, 775–86 (2016).
64. Allette Y. M., et al. Identification of a functional interaction of HMGB1 with Receptor for Advanced Glycation End-products in a model of neuropathic pain. Brain. Behav. Immun. 42, 169–77 (2014).
65. Grace P. M., et al. Pathological pain and the neuroimmune interface. Nat. Rev. Immunol. 14, 217–
31 (2014).
66. Tsuda M., et al. JAK-STAT3 pathway regulates spinal astrocyte proliferation and neuropathic pain maintenance in rats. Brain 134, 1127–39 (2011).
67. Tsuda M., et al. P2X4 receptors induced in spinal microglia gate tactile allodynia after nerve injury. Nature 424, 778–83 (2003).
68. Liu X.-X., et al. Regnase-1 in microglia negatively regulates high mobility group box 1-mediated inflammation and neuronal injury. Sci. Rep. 6, 24073 (2016).
69. Christianson C. A., et al. Spinal TLR4 mediates the transition to a persistent mechanical
52
hypersensitivity after the resolution of inflammation in serum-transferred arthritis. Pain 152, 2881–91 (2011).
70. Vetreno R. P., et al. Increased receptor for advanced glycation end product expression in the human alcoholic prefrontal cortex is linked to adolescent drinking. Neurobiol. Dis. 59, 52–62 (2013).
71. Pichiule P., et al. Hypoxia-inducible factor-1 mediates neuronal expression of the receptor for advanced glycation end products following hypoxia/ischemia. J. Biol. Chem. 282, 36330–40 (2007).
72. D’Mello R., et al. Spinal cord mechanisms of pain. Br. J. Anaesth. 101, 8–16 (2008).
73. Huang J., et al. A neuronal circuit for activating descending modulation of neuropathic pain. Nat.
Neurosci. 22, 1659–1668 (2019).
74. Stamford J. A. Descending control of pain. Br. J. Anaesth. 75, 217–27 (1995).
75. Vanegas H., et al. Descending control of persistent pain: inhibitory or facilitatory? Brain Res.
Brain Res. Rev. 46, 295–309 (2004).
76. Cucchiaro G., et al. The locus coeruleus nucleus as a site of action of the antinociceptive and behavioral effects of the nicotinic receptor agonist, epibatidine. Neuropharmacology 50, 769–776 (2006).
77. Jones S. L., et al. Inhibition of spinal nociceptive transmission from the midbrain, pons and medulla in the rat: activation of descending inhibition by morphine, glutamate and electrical stimulation. Brain Res. 460, 281–296 (1988).
78. Peyron C., et al. A mutation in a case of early onset narcolepsy and a generalized absence of hypocretin peptides in human narcoleptic brains. Nat. Med. 6, 991–7 (2000).
79. Hagan J. J., et al. Orexin A activates locus coeruleus cell firing and increases arousal in the rat.
Proc. Natl. Acad. Sci. U. S. A. 96, 10911–6 (1999).
80. Sakurai T., et al. Orexins and Orexin Receptors: A Family of Hypothalamic Neuropeptides and G Protein-Coupled Receptors that Regulate Feeding Behavior. Cell 92, 573–585 (1998).
81. de Lecea L., et al. The hypocretins: hypothalamus-specific peptides with neuroexcitatory activity.
Proc. Natl. Acad. Sci. U. S. A. 95, 322–7 (1998).
82. Marcus J. N., et al. Differential expression of orexin receptors 1 and 2 in the rat brain. J. Comp.
Neurol. 435, 6–25 (2001).
83. Kitamura E., et al. The effect of orexin-A on the pathological mechanism in the rat focal cerebral ischemia. Neurosci. Res. 68, 154–157 (2010).
84. HALEY T. J., et al. Pharmacological effects produced by intracerebral injection of drugs in the conscious mouse. Br. J. Pharmacol. Chemother. 12, 12–5 (1957).
85. Villano I., et al. Basal Forebrain Cholinergic System and Orexin Neurons: Effects on Attention.
Front. Behav. Neurosci. 11, 10 (2017).
53
86. Ouyang Y.-B., et al. Selective dysfunction of hippocampal CA1 astrocytes contributes to delayed neuronal damage after transient forebrain ischemia. J. Neurosci. 27, 4253–60 (2007).
87. Harada S., et al. Involvement of GPR40, a long-chain free fatty acid receptor, in the production of central post-stroke pain after global cerebral ischemia. Eur. J. Pharmacol. 744, 115–23 (2014).
88. Yamamoto T., et al. Anti-mechanical allodynic effect of intrathecal and intracerebroventricular injection of orexin-A in the rat neuropathic pain model. Neurosci. Lett. 347, 183–186 (2003).
89. Yamamoto T., et al. Analgesic effect of intrathecally administered orexin-A in the rat formalin test and in the rat hot plate test. Br. J. Pharmacol. 137, 170–176 (2002).
90. Toyama S., et al. The analgesic effect of orexin-A in a murine model of chemotherapy-induced neuropathic pain. Neuropeptides 61, 95–100 (2017).
91. Lee H.-J., et al. Stress induces analgesia via orexin 1 receptor-initiated endocannabinoid/CB1 signaling in the mouse periaqueductal gray. Neuropharmacology 105, 577–586 (2016).
92. Burgess C. R., et al. Narcolepsy: neural mechanisms of sleepiness and cataplexy. J. Neurosci. 32, 12305–11 (2012).
93. Azhdari-Zarmehri H., et al. Orexin-a modulates firing of rat rostral ventromedial medulla neurons: an in vitro study. Cell J. 17, 163–70 (2015).
94. Ciriello J., et al. Effects of hypocretin and norepinephrine interaction in bed nucleus of the stria terminalis on arterial pressure. Neuroscience 255, 278–91 (2013).
95. Mori T., et al. Narcolepsy-like sleep disturbance in orexin knockout mice are normalized by the 5-HT1A receptor agonist 8-OH-DPAT. Psychopharmacology (Berl). 233, 2343–53 (2016).
96. Ochi T., et al. The antinociceptive effect of FR140423 in mice: involvement of spinal α2 -adrenoceptors. Eur. J. Pharmacol. 400, 199–203 (2000).
97. Stone L. S., et al. The alpha2a adrenergic receptor subtype mediates spinal analgesia evoked by alpha2 agonists and is necessary for spinal adrenergic-opioid synergy. J. Neurosci. 17, 7157–65 (1997).
98. Newman-Tancredi A., et al. NLX-112, a highly selective 5-HT1A receptor agonist, mediates analgesia and antidepressant-like activity in rats via spinal cord and prefrontal cortex 5-HT1A receptors, respectively. Brain Res. 1688, 1–7 (2018).
99. Song G. J., et al. A Bcr-Abl Inhibitor GNF-2 Attenuates Inflammatory Activation of Glia and Chronic Pain. Front. Pharmacol. 10, 543 (2019).
100. Duffy C. M., et al. Role of orexin A signaling in dietary palmitic acid-activated microglial cells.
Neurosci. Lett. 606, 140–4 (2015).
101. Ramos A. J., et al. The 5HT1A receptor agonist, 8-OH-DPAT, protects neurons and reduces astroglial reaction after ischemic damage caused by cortical devascularization. Brain Res. 1030, 201–20 (2004).
102. Gao J., et al. Dexmedetomidine modulates neuroinflammation and improves outcome via
alpha2-54
adrenergic receptor signaling after rat spinal cord injury. Br. J. Anaesth. 123, 827–838 (2019).
103. Sharifi H., et al. 8-OH-DPAT (5-HT1A agonist) Attenuates 6-Hydroxy- dopamine-induced catalepsy and Modulates Inflammatory Cytokines in Rats. Iran. J. Basic Med. Sci. 16, 1270–5 (2013).
104. Sakakiyama M., et al. Preventive and Alleviative Effect of Tramadol on Neuropathic Pain in Rats: Roles of α2-Adrenoceptors and Spinal Astrocytes. J. Pharmacol. Sci. 124, 244–257 (2014).
55
主論文
1. Matsuura W., Nakamoto K., Tokuyama S. The involvement of DDAH1 in the activation of spinal NOS signaling in early stage of mechanical allodynia induced by exposure to ischemic stress in mice. Biol.
Pharm. Bull., 42, 1569-1574 (2019)
2. Matsuura W., Harada S., Liu K., Nishibori M., Tokuyama S. Evidence of a role for spinal HMGB1 in ischemic stress-induced mechanical allodynia in mice. Brain Res., 1687, 1-10 (2018)
3. Matsuura W., Nakamoto K., Tokuyama S. Involvement of descending pain control system regulated by orexin receptor signaling in the induction of central post-stroke pain in mice. Eur. J. Pharmacol., in press